Mr Bradley Daniel Chmielewski, MD | |
2800 Campus Dr Ste 10, Plymouth, MN 55441-8812 | |
(763) 559-2171 | |
Not Available |
Full Name | Mr Bradley Daniel Chmielewski |
---|---|
Gender | Male |
Speciality | Pulmonary Disease |
Experience | 21 Years |
Location | 2800 Campus Dr Ste 10, Plymouth, Minnesota |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063618023 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | 49124 (Minnesota) | Secondary |
207RC0200X | Internal Medicine - Critical Care Medicine | 49124 (Minnesota) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
North Memorial Health | Robbinsdale, MN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
North Memorial Health Care | 0042123028 | 483 |
Respiratory Consultants Pa | 6204736853 | 17 |
News Archive
Gemino Healthcare Finance today announced it has been acquired by Solar Senior Capital Ltd. ("Solar Senior Capital"). Over the last seven years, Philadelphia-based Gemino has earned a strong reputation in the market as a provider of asset-based and term financing solutions for small to mid-size healthcare companies.
Sucampo Pharmaceuticals, Inc. and Abbott today announced that a pivotal phase 3 clinical trial of lubiprostone for chronic idiopathic constipation (CIC) in Japanese patients met its primary endpoint with statistical significance and demonstrated a safety profile consistent with previously reported clinical lubiprostone data.
CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).
Researchers have uncovered ethnic differences in the risk of neonatal mortality and morbidity (disease) in the neonatal intensive care units (NICU).
› Verified 6 days ago
Entity Name | Respiratory Consultants Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1356439277 PECOS PAC ID: 6204736853 Enrollment ID: O20040112000044 |
News Archive
Gemino Healthcare Finance today announced it has been acquired by Solar Senior Capital Ltd. ("Solar Senior Capital"). Over the last seven years, Philadelphia-based Gemino has earned a strong reputation in the market as a provider of asset-based and term financing solutions for small to mid-size healthcare companies.
Sucampo Pharmaceuticals, Inc. and Abbott today announced that a pivotal phase 3 clinical trial of lubiprostone for chronic idiopathic constipation (CIC) in Japanese patients met its primary endpoint with statistical significance and demonstrated a safety profile consistent with previously reported clinical lubiprostone data.
CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).
Researchers have uncovered ethnic differences in the risk of neonatal mortality and morbidity (disease) in the neonatal intensive care units (NICU).
› Verified 6 days ago
Entity Name | North Memorial Health Care |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1851344907 PECOS PAC ID: 0042123028 Enrollment ID: O20040122000470 |
News Archive
Gemino Healthcare Finance today announced it has been acquired by Solar Senior Capital Ltd. ("Solar Senior Capital"). Over the last seven years, Philadelphia-based Gemino has earned a strong reputation in the market as a provider of asset-based and term financing solutions for small to mid-size healthcare companies.
Sucampo Pharmaceuticals, Inc. and Abbott today announced that a pivotal phase 3 clinical trial of lubiprostone for chronic idiopathic constipation (CIC) in Japanese patients met its primary endpoint with statistical significance and demonstrated a safety profile consistent with previously reported clinical lubiprostone data.
CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).
Researchers have uncovered ethnic differences in the risk of neonatal mortality and morbidity (disease) in the neonatal intensive care units (NICU).
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Mr Bradley Daniel Chmielewski, MD 2800 Campus Dr Ste 10, Plymouth, MN 55441-8812 Ph: (763) 559-2171 | Mr Bradley Daniel Chmielewski, MD 2800 Campus Dr Ste 10, Plymouth, MN 55441-8812 Ph: (763) 559-2171 |
News Archive
Gemino Healthcare Finance today announced it has been acquired by Solar Senior Capital Ltd. ("Solar Senior Capital"). Over the last seven years, Philadelphia-based Gemino has earned a strong reputation in the market as a provider of asset-based and term financing solutions for small to mid-size healthcare companies.
Sucampo Pharmaceuticals, Inc. and Abbott today announced that a pivotal phase 3 clinical trial of lubiprostone for chronic idiopathic constipation (CIC) in Japanese patients met its primary endpoint with statistical significance and demonstrated a safety profile consistent with previously reported clinical lubiprostone data.
CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).
Researchers have uncovered ethnic differences in the risk of neonatal mortality and morbidity (disease) in the neonatal intensive care units (NICU).
› Verified 6 days ago
Erica N. Roberson, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 15700 37th Ave N, #300, Plymouth, MN 55446 Phone: 612-871-1145 Fax: 612-870-5491 | |
Dr. Thomas John Kaminsky, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 15700 37th Ave N Ste 300, Plymouth, MN 55446 Phone: 612-871-1145 Fax: 612-870-5491 | |
Alfred P. Chiang, D.O. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2700 Campus Dr, Suite 100, Plymouth, MN 55441 Phone: 763-519-0634 Fax: 763-519-0636 | |
Daniela T Ouzounova, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2855 Campus Dr, Ste. 400, Plymouth, MN 55441 Phone: 763-577-7400 | |
Stephanie Norris, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 3007 Harbor Ln N, Plymouth, MN 55447 Phone: 952-993-8900 | |
Dr. Daniel Mark Van Handel, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 15700 37th Ave N Ste 300, Plymouth, MN 55446 Phone: 612-871-1145 Fax: 612-870-5491 |